

10/083336

Smith, Gambrell & Russell, LLP
ATTORNEYS AT LAWATLANTA OFFICE
****SUITE 3100, PROMENADE II
1330 PEACHTREE STREET, N.E.
ATLANTA, GEORGIA 30309-3602
TELEPHONE:
(404) 815-3500
FACSIMILE
(404) 815-3309Suzannah K. Sundby, Esq.
Direct Dial: 202-263-4332
Direct Fax: 202-263-4352
ssundby@sgrlaw.comSUITE 800
1000 N STREET, N.W.WASHINGTON, D.C. 20036
TELEPHONE (202) 263-4300
FACSIMILE (202) 263-4329
WEBSITE WWW.SGRLAW.COM

Established 1893

5 April 2005

FLORIDA OFFICE
****SUITE 2800, BANK OF AMERICA TOWER
60 NORTH LAURA STREET
JACKSONVILLE, FL 32202
TELEPHONE
(904) 598-8100
FACSIMILE
(904) 598-6300Certificate
APR 11 2005
of Correction

Fax

To: USPTO – Certificate of
Corrections Branch

From: Suzannah K. Sundby

Fax: (703) 308-7048

Phone:

Date: 5 April 2005

Pages: 5 (including cover page)

In re Application of:

OLSON, *et al.*

Serial No.: 10/083,336

Filed: 27 February 2002

For: RICIN VACCINE AND METHODS OF MAKING AND
USING THEREOF

Art Unit: 1652

Examiner: Manjunath N. RAO

Atty. Dckt: 034047.016

The following are being submitted via facsimile to the United States Patent and Trademark
Office on 5 April 2005:Request for Certificate of Correction under 37 CFR §1.323 and Form PTO/SB/44 Certificate
of Correction

Certificate Mailing or Transmission under 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being transmitted by facsimile on the date shown below to the
United States Patent and Trademark Office at (703) 308-7048

on 5 April 2005, by Suzannah K. Sundby

Signed: Suzannah Sundby

APR 11 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

OLSON, *et al.*

Serial No.: 10/083,336

Filed: 27 February 2002

For: RICIN VACCINE AND METHODS OF MAKING AND
USING THEREOF

Patent No. 6,869,787 B2

Art Unit: 1652

Examiner: RAO, Manjunath N.

Atty. Dckt: 034047.016

**REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 CFR §1.323**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Mail Stop: Certificate of Corrections Branch

Dear Sir:

The undersigned, on behalf of the Applicants, hereby requests official correction of U.S. Patent No. 6,869,787 B2. Attached is Form PTO/SB/44, in duplicate.

Upon reviewing the issued patent, we would like to note the errors as follows:

On the first page, in the section for Inventors, "Ross D. LeClaire, Frederick, MD (US)" should be deleted.

In the claims on pages 41-44, claims 1, 2, 5, 14, 19 and 21 should read as follows, with the correct text being underlined and deletions are in strike-through:

1. An isolated polypeptide consisting of a polypeptide sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:11, which lacks detectable N-glycosidase-rRNA activity or exhibits reduced N-glycosidase-rRNA ~~tivity~~ activity as compared to a wild type ricin A chain.


SGRDC\230802.1

APR 11 2005

2. The polypeptide of claim 1, wherein the polypeptide ~~retai~~ retains the neutralizing immunological epitope of wild type ricin A chain.
5. An isolated ~~polypeptide~~ polypeptide consisting of SEQ ID NO:4.
14. An isolated polypeptide comprising a polypeptide sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:11, which lacks detectable N-glycosidase-rRNA activity or exhibits reduced N-glycosidase-~~rRNA~~ rRNA activity as compared to a wild type ricin A chain.
19. The polypeptide of claim 14, made by recombinant DNA ~~techniques~~ techniques.
21. A pharmaceutical composition comprising at least one ~~poly-peptide~~ polypeptide of claim 14 in an ~~immunogenic~~ immunogenic amount and a pharmaceutically acceptable vehicle.

Since the errors were on the part of the U.S. Patent and Trademark Office, no fee are necessary. However, should any fees be necessary to correct the patent as requested herein, the fees are hereby authorized to be charged to **Deposit Account No. 210-380, Attorney Docket No. 034047.016 (RIID 01-58)**.

Respectfully submitted,


Suzannah K. Sundby
Reg. No. 43,172

Date: 5 April 2005
SMITH, GAMBRELL & RUSSELL, LLP
1850 M Street, NW, #800
Washington, DC 20036
Direct: 202-263-4332

Certificate Mailing or Transmission under 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being:

☒ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 746-
~~4000~~ **308-7048**

On 5 April 2005 by Suzannah K. Sundby

Signed: 

SGRD0230802.1

APR 11 2005

PTO/SB/44 (04-04)

Approved for use through 04/30/2007. OMB 0851-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,869,787 B2

DATED :22 March 2005

INVENTOR(S) :Olson et al.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

On the first page, in the section for Inventors, "Ross D. LeClaire, Frederick, MD (US)" should be deleted.

On pages 41-44 under "We claim:" please amend the claims 1, 2, 5, 14, 19 and 21 as follows:

1. An isolated polypeptide consisting of a polypeptide sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:11, which lacks detectable N-glycosidase-rRNA activity or exhibits reduced N-glycosidase-rRNA ~~ivity~~ activity as compared to a wild type ricin A chain.

2. The polypeptide of claim 1, wherein the polypeptide ~~retai~~ retains the neutralizing immunological epitope of wild type ricin A chain.

5. An isolated ~~polypeptide~~ polypeptide consisting of SEQ ID NO:4.

14. An isolated polypeptide comprising a polypeptide sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:11, which lacks detectable N-glycosidase-rRNA activity or exhibits reduced N-glycosidase-rRNA rRNA activity as compared to a wild type ricin A chain.

19. The polypeptide of claim 14, made by recombinant DNA ~~techniques~~ techniques.

21. A pharmaceutical composition comprising at least one ~~poly-peptide~~ polypeptide of claim 14 in an ~~immunogenic~~ immunogenic amount and a pharmaceutically acceptable vehicle.

MAILING ADDRESS OF SENDER: Smith, Gambrell & Russell LLP
1850 M Street, NW, Suite 800
Washington, DC 20036

PATENT NO. 6,869,787 B2

Not for use as a cover sheet
1

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

APR 11 2005